Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 94
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | ||
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | ||
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | ||
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | ||
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | ||
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | ||
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | ||
| NCT03627403 | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | ||
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | ||
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | ||
| NCT02228525 | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | ||
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | ||
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | ||
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | ||
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | ||
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | ||
| NCT02137356 | Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer | ||
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | ||
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | ||
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | ||
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | ||
| NCT02431364 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults | ||
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | ||
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | ||
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | ||
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | ||
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | ||
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | ||
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | ||
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | ||
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | ||
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | ||
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | ||
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | ||
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | ||
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | ||
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | ||
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | ||
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | ||
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | ||
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | ||
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | ||
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | ||
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | ||
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | ||
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | ||
| NCT02078349 | Phase I Study of KPT330 in Asian Patients |
